Tufts Researchers Report Experimental 'Four‑in‑One' Peptide That Blunted Appetite in Preclinical Tests

Tufts University scientists reported an experimental peptide that activates four gut‑derived hormone pathways produced larger appetite‑suppressing and weight‑loss effects in preclinical studies and appeared to avoid some side effects seen with current GLP‑1 therapies, according to a paper published in the Journal of the American Chemical Society.

Authors led by chemistry professor Krishna Kumar and graduate student Tristan Dinsmore described a single synthetic peptide engineered to act like GLP‑1, glucose‑dependent insulinotropic polypeptide (GIP), glucagon and peptide YY (PYY). The team said the molecule is intended to "nudge" multiple biological "dimmer switches" that regulate appetite, metabolism and energy use rather than strongly activating a single pathway, a strategy they argue could improve efficacy and tolerability.

In interviews and in the paper, the researchers said the four‑target approach produced greater weight‑loss effects in their experimental models than single or dual‑target drugs currently used to treat obesity and type 2 diabetes. Lead author Dinsmore told media outlets the peptide was designed to mimic the weight‑loss profile of bariatric surgery while avoiding the more severe adverse events seen with some existing medications.

"We built a single experimental peptide that works like four hormones at once, so we're not pushing one button too hard," Dinsmore said. "Instead, we're nudging four 'dimmer switches' together... [It helps to] balance things out." The paper reports that adding PYY, a gut hormone released after meals that reduces appetite and slows gastric emptying through mechanisms distinct from GLP‑1 and GIP, was technically challenging because PYY is structurally unrelated to the other peptides.

The Tufts team compared their four‑in‑one design to currently available therapies that target one or two pathways, such as semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound). Krishna Kumar said one limitation of existing GLP‑1 receptor agonists is nausea and other gastrointestinal side effects, which contribute to early discontinuation: "As much as 40 percent of people using these drugs give up after the first month," he told Fox News.

Researchers noted that, while weekly injectable GLP‑1 and dual‑agonist drugs have helped millions of adults lose weight and improve glucose control, they are not without concerns. Published reports and user accounts have described side effects ranging from nausea and vomiting to more severe complaints, and some cases of serious adverse events have prompted litigation and further investigation. Regulatory agencies have not established direct causal links for many reported serious outcomes, and the authors emphasized that safety and efficacy must be assessed in human trials.

The Tufts paper also situates the work amid other experimental multi‑agonist therapies. A triple‑agonist compound in clinical testing, retatrutide, targets three hormone pathways; Tufts scientists say their four‑receptor approach may further broaden the biologic targets and potentially smooth variability in individual responses. Martin Beinborn, a visiting scholar on the project, said broader receptor engagement could "improve the chances of averaging out such variation toward the goal of achieving greater and more consistent overall effectiveness."

Clinical context remains important: established agents produce a range of average weight loss in trials, and bariatric surgery continues to produce larger, more durable reductions in body weight for many patients, while carrying operative and long‑term risks of its own. Observational data indicate that, for some patients, weight reaccumulates after discontinuing medication; the researchers cited literature showing substantial weight regain within a year for many people who stop therapy.

The Tufts peptide remains experimental and has not been tested in humans. The authors state that additional preclinical safety work and regulatory review are required before any clinical trials could begin. Until then, the findings describe a laboratory advance and a strategy for multi‑receptor pharmacology rather than an immediately available treatment option.